FDA Approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata

The FDA approval of deuruxolitinib, an oral JAK inhibitor, offers a promising new treatment for severe alopecia areata (AA), an autoimmune condition causing non-scarring hair loss. This approval is based on two phase 3 trials, THRIVE-AA1 and THRIVE-AA2, involving 1,220 patients, which showed significant hair regrowth compared to placebo. At 24 weeks, 29.6% of participants on an 8 mg dose and 41.5% on a 12 mg dose achieved a SALT score of ≤20. Deuruxolitinib demonstrated a manageable side effect profile, primarily headaches and acne, without significant cardiovascular risks, making it a safer alternative to other JAK inhibitors. Further research is needed to assess long-term safety and effects post-treatment.